A Budget Impact Analysis of Bronchial Thermoplasty for Severe Asthma in Clinical Practice

Menzella, Francesco; Zucchi, Luigi; Piro, Roberto; Galeone, Carla; Castagnetti, Claudia; Facciolongo, Nicola

doi:10.1007/s12325-014-0135-7

Cited by 14 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the increase in direct cost of BT, the treatment of asthmatics with either BT or omalizumab, in addition to standard care, may not only help clinicians meet the needs of a greater number of patients, but may also decrease emergency room visits and hospitalization and make savings in the long run (28).…”

Section: Resultsmentioning

confidence: 99%

Bronchial thermoplasty: a non‐pharmacological approach

Singh

Tiwari

2015

Clinical Respiratory J

View full text Add to dashboard Cite

Introduction: Asthma is a chronic inflammatory disorder of the airway characterized by the episodic symptoms of breathlessness, wheezes and cough. Even with the use of maximum anti-asthmatic pharmacological treatment sometimes it remains uncontrolled. For such patients, bronchial thermoplasty is the new mode of treatment.Objective: To review published article on bronchial thermoplasty. Methods: We identified 102 English articles on PubMed, and 56 were excluded by the abstract. The remaining articles were retrieved for full-text detailed evaluation by authors, and 28 relevant articles were selected for final review. Results: Bronchial thermoplasty is the radiofrequency ablation of the airway smooth muscle with the help of flexible fiberoptic bronchoscope. It reduces the smooth muscle mass of the bronchial wall and decreases its contractility. Conclusion: Bronchial thermoplasty causes improvement in the quality of life, and causes reduction in the emergency room visit and exacerbation due to asthma. Long-term safety has been established by various prospective studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Bronchial thermoplasty: a non‐pharmacological approach

Singh

Tiwari

2015

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…BT is an expensive procedure, but recent studies have shown that the obvious high cost may be at least partially balanced by the reduction in costs due to decrease in acute exacerbations of asthma requiring emergency department visits and the effects of improved quality of life for patients [32]. A subsequent study has confirmed that BT has a 60% chance to be more cost effective as compared with omalizumab and standard therapy on the willingness-to pay of $100,000/qualityadjusted life year [33].…”

Section: Pharmacoeconomics Of Bronchial Thermoplastymentioning

confidence: 99%

Bronchial Thermoplasty: A New Therapeutic Option in Severe Uncontrolled Asthma

Kumar¹

2019

Interventional Pulmonology - Principles, Practices and Updates [Working Title]

View full text Add to dashboard Cite

Bronchial thermoplasty (BT) is a new endoscopic treatment approved by the US Food and Drug Administration (FDA) in the management of severe refractory asthma involving the delivery of controlled, therapeutic radiofrequency (RF) energy to the airway wall. It is based on the premise of controlling bronchospasm through a reduction of airway smooth muscle (ASM). Several clinical trials have demonstrated improvements in asthma-related quality of life and a reduction in the number of exacerbations following treatment with BT. However, several questions remain regarding the use of BT, mechanism of action, selection of appropriate patients, and long-term effects. Further studies are expected to elucidate the underlying mechanisms that result in these improvements. This chapter discusses key aspects of BT with a focus on the potential clinical effects of this promising procedure. It also offers insight into the barriers to implementing a successful BT program and strategies for overcoming them.

show abstract

“…However, these costs are lower if compared with those associated with the use of biologic therapies for serious asthma (in particular, omalizumab), especially for long-term treatments, as demonstrated by several studies. 76 , 77 There are still many open questions about the mechanism of action, selection of patients and their management. However, a reduction of airway smooth muscle and inflammation has been observed, 78 , 79 also with regard to a possible reduction of blood eosinophils after BT.…”

Section: Not Only Biologic Therapies: Btmentioning

confidence: 99%

Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?

Menzella

Galeone

Bertolini

et al. 2017

JAA

Self Cite

View full text Add to dashboard Cite

The increasing understanding of the molecular biology and the etiopathogenetic mechanisms of asthma helps in identification of numerous phenotypes and endotypes, particularly for severe refractory asthma. For a decade, the only available biologic therapy that met the unmet needs of a specific group of patients with severe uncontrolled allergic asthma has been omalizumab. Recently, new biologic therapies with different mechanisms of action and targets have been approved for marketing, such as mepolizumab. Other promising drugs will be available in the coming years, such as reslizumab, benralizumab, dupilumab and lebrikizumab. Moreover, since 2010, bronchial thermoplasty has been successfully introduced for a limited number of patients. This is a nonpharmacologic endoscopic procedure which is considered a promising therapy, even though several aspects still need to be clarified. Despite the increasing availability of new therapies, one of the major problems of each treatment is still the identification of the most suitable patients. This sudden abundance of therapeutic options, sometimes partially overlapping with each other, increases the importance to identify new biomarkers useful to guide the clinician in selecting the most appropriate patients and treatments, without forgetting the drug-economic aspects seen in elevated direct cost of new therapies. The aim of this review is, therefore, to update the clinician on the state of the art of therapies available for refractory asthma and, above all, to give useful directions that will help understand the different choices that sometimes partially overlap and to dispel the possible doubts that still exist.

show abstract

A Budget Impact Analysis of Bronchial Thermoplasty for Severe Asthma in Clinical Practice

Cited by 14 publications

References 14 publications

Bronchial thermoplasty: a non‐pharmacological approach

Bronchial thermoplasty: a non‐pharmacological approach

Bronchial Thermoplasty: A New Therapeutic Option in Severe Uncontrolled Asthma

Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?

Contact Info

Product

Resources

About